Safety and biologic activity of a bispecific T cell receptor targeting HIV Gag in males living with HIV: a first-in-human trial
Linos Vandekerckhove(Ghent University), S. Fidler(NIHR Imperial Biomedical Research Centre), Kehmia Titanji(Immunocore (United Kingdom)), Sylvie Moureau(Immunocore (United Kingdom)), Jason Wustner(Morphotek (United States)), Agatha Treveil(Immunocore (United Kingdom)), Beatriz Mothe(IrsiCaixa), Jo Fox(Guy's and St Thomas' NHS Foundation Trust), Adel Benlahrech(Immunocore (United Kingdom)), Sabine Allard(Vrije Universiteit Brussel), Andrew Whale(Karus Therapeutics (United Kingdom)), Lucy Dorrell(MRC Human Immunology Unit), Rory Harrison(Immunocore (United Kingdom)), Moreno Guillén S(Instituto Cajal), Zoë Wallace(Immunocore (United Kingdom)), James Clubley(Immunocore (United Kingdom)), Mareva Delporte(Radboud University Nijmegen), Praveen Singh(Immunocore (United Kingdom)), Frank A Post(King's College Hospital NHS Foundation Trust), Jordi Navarro(Vall d'Hebron Institut de Recerca), Borja Mora-Peris(NIHR Imperial Biomedical Research Centre), Marta Boffito(Chelsea and Westminster Hospital), Yuan Yuan(Immunocore (United Kingdom)), Haseeb Rahman(Immunocore (United Kingdom)), Vicente Estrada(Hospital Clínico San Carlos), Alison Uriel(North Manchester General Hospital), Miriam Hock(Immunocore (United Kingdom)), Jonathan M. G. Chamberlain(Immunocore (United Kingdom))
Cited by 1
Related Papers
A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans
|Journal of General Virology|2004|210
A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques
|Journal of Translational Medicine|2015|97
Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1
|Journal of Antimicrobial Chemotherapy|2015|65
Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature
|Oncotarget|2015|48
Functional characterization of a novel somatic oncogenic mutation of PIK3CB
|Signal Transduction and Targeted Therapy|2017|44